- Services
- Team
- Patient Education
- Diagnosing MS
- Understanding Some Basics About MS
- Relapsing Remitting MS
- Secondary Progressive MS
- Primary Progressive MS
- Preparing for Your New Patient Visit
- Preparing for a Spinal Tap
- Injection & Medication Counseling
- Relapse vs. Pseudorelapse
- Neuromyelitis Optics vs. Multiple Sclerosis
- Resources
- FAQ
- Research
- News
- Contact
- Leave a Review
Alemtuzumab FDA Decision
by James W. Stark
Alemtuzumab (Lemtrada and previously known as Campath) has not been approved by the FDA during their recent evaluation. The FDA sites significant concerns over the medication's safety profile as well as the design of some of the studies. The FDA has requested more safety and efficacy data from future clinical trials. Genzyme plans on appealing this decision.
News Date :
Friday, January 3, 2014 - 01:27
IMSMP
Because you deserve only the best in MS healthcare. Experience the difference.
News & Events
Newsletter Sign Up
Join our mailing list today! Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.
* We don’t share your information with anyone.